Abbott Laboratories Corporation

University of Pittsburgh

Mark Anthony McCamish

Terrence B Mazer

Joseph E Walton

Carl Joseph Piontek

Andre Daab-Krzykowski

Ronita K Geckle

Stephen Joseph Demichele

Robert L Joseph

Frederick Oliver Cope

Bonnie Chandler Abbruzzese

William Guy Pierson

Susan Beth Duel

Robert H Miller

Ronald T Stanko

Jeffrey R Ross

James L Tiefenthal

Roger G Danis

James P Hayes

Andrea L Senokozliff-Englehart

The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of &#x3c9;-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.

Composition for the prevention and treatment of cachexia

The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of &ohgr;-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.

Method for the prevention and treatment of cachexia and anorexia

The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of &ohgr;-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof, of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.

The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of .omega.-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.

Treating mammals having ischemic bowel with a therapeutic quantity of pyruvate enterally or parenterally will retard neutrophil infiltration and retain morphology during and following the bowel ischemia. The pyruvate is introduced into the patient enterally or parenterally during the bowel ischemia or the succeeding bowel reperfusion and, preferably, prior to the bowel ischemia. The pyruvate dosage is from 1% to 20% by weight of the patient's caloric intake.

Retarding neutrophil infiltration ad morphologic reduction in ischemic

A method is disclosed for modifying a liquid enteral nutritional product during delivery thereof from a supply container to a feeding tube delivering the nutritional product to the gastrointestinal tract of a patient. During enteral tube feeding the nutritional product passes through a formulation chamber, e.g., a drip chamber, having located therein at least one controlled release dosage form unit containing at least one beneficial agent. The beneficial agent may be selected from nutrients, medicaments, probiotics, or diagnostic agents or mixtures thereof, and any such together with a physiologically acceptable marker dye in controlled release dosage form and/or the same or different additional beneficial agent not in controlled release dosage form. Controlled release dosage forms may be of a conventional sustained release type or an osmotically driven delivery device.

Method of altering composition of nutritional product during enteral

An apparatus is disclosed for modifying a liquid enteral nutritional product during delivery thereof from a supply thereof, such as a hangable container, to a feeding tube delivering the liquid enteral nutritional product to the gastrointestinal tract of a patient. The apparatus has at least one formulation chamber, such as a drip chamber, with at least one controlled release dosage form unit in the form of a coated tablet, osmotically driven device, coated capsule, microencapsulated microspheres, agglomerated molecular sieving type material, or a quantity of fine hollow permeable fibers located therein. The controlled release dosage form unit or units contain at least one beneficial agent selected from nutrients, medicaments, probiotics, or diagnostic agents or mixtures thereof, to any of which a physiologically acceptable marker dye in controlled release dosage form and/or the same or different beneficial agent not in controlled release dosage form may be added. A liquid nutritional product flows through the formulation chamber during enteral tube feeding of a patient.

Apparatus for altering composition of nutritional product during enteral

A therapeutic method is provided to reduce ischemia/reperfusion injury to the heart muscle by perfusing pyruvylglycine into the circulatory system of a patient who has had a heart attack or suffered coronary occlusion.

Use of pyruvylglycine to treat ischemia/reperfusion injury following

A laparoscopic jejunostomy instrumentation kit includes components for securing a patient's intestine in apposition to the patient's abdominal wall and for creating a stoma through the patient's abdominal wall and intestinal wall, a jejunostomy tube, and an enclosure for containing the other components of the kit. In preferred embodiments the kit includes T-Fastener assemblies, needles, syringes, a dilator, a peel-away sheath and a gastrostomy tube.

Laparoscopic jejunostomy instrumentation kit

An apparatus may be employed for determining the relaxation rate of a muscle which has been caused to contract in response to an electrical stimulus. The relaxation rate may be used in evaluating a person's nutritional status. The apparatus has support for supporting the forearm and wrist of a person in a palm-up position with the wrist extended. An electrical stimulus is applied to the person's ulnar nerve, and the force exerted upon a load cell by the person's thumb is measured. A computer is employed for receiving, storing, plotting and analyzing the force data collected by a transducer.

Growing community of inventors

Worthington, OH, United States of America

Mark Anthony McCamish